G
Giuseppe Minniti
Researcher at University of Siena
Publications - 219
Citations - 10214
Giuseppe Minniti is an academic researcher from University of Siena. The author has contributed to research in topics: Radiation therapy & Radiosurgery. The author has an hindex of 50, co-authored 189 publications receiving 7617 citations. Previous affiliations of Giuseppe Minniti include Sapienza University of Rome & The Royal Marsden NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study
Antonio Rozzi,C. Nardoni,Michela Corona,Maria Rosa Restuccia,Alessandra Fabi,Emilio Bria,Giuseppe Minniti,Gaetano Lanzetta +7 more
TL;DR: A single dose of palonosetron before the initiation of multiple oral doses of TMZ, in patients on treatment with steady doses of dexamethasone, provides a high protection against CINV throughout the overall phase (0–168 h).
Journal ArticleDOI
Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study
Antonio Rozzi,Daniele Santini,Margherita Salerno,Francesca Bordin,Andrea Mancuso,Giuseppe Minniti,C. Nardoni,Michela Corona,Pina Tiziana Falbo,Federica Recine,Gaetano Lanzetta +10 more
TL;DR: This is the first study which evaluated the role of anthracyclines as third-line chemotherapy in metastatic TCC, and despite its manageable profile of toxicity, PLD showed modest activity.
Journal ArticleDOI
Treatment of glioblastoma in elderly patients: an overview of current treatments and future perspective
TL;DR: The addition of concomitant and/or adjuvant chemotherapy with temozolomide to radiotherapy, which is currently the standard treatment in adults with glioblastoma, is emerging as an effective therapeutic option for older patients with favorable prognostic factors.
Journal ArticleDOI
Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers
Giuseppe Minniti,Antonella Arcella,Claudia Scaringi,Gaetano Lanzetta,Domenica Di Stefano,Stefania Scarpino,Andrea Pace,Felice Giangaspero,Mattia Falchetto Osti,Riccardo Maurizi Enrici +9 more
TL;DR: The study indicates that RT with concomitant and adjuvant TMZ is a relatively safe treatment associated with longer survival in patients with 1p/19q codeleted and IDH1 mutated tumors.